ndothelium-derived nitric oxide (EDNO), which accounts for the major biological properties of the endothelium-derived relaxing factor, 1 is synthesized from L-arginine via NO synthase (NOS). 2 NO is a single molecule with profound effects on cardiovascular physiology: it inhibits pathologic processes such as abnormal arterial vasomotion, thrombosis, and vascular smooth muscle cell proliferation. [3] [4] [5] In humans, platelet-derived NO (PDNO) is also produced by the L-arginine/NO pathway through constitutive NOS. 6 Platelet aggregation is inhibited by L-arginine, a precursor of NO, potentiated by NGmonomethyl-L-arginine, an inhibitor of NOS, 6, 7 and is accompanied by an increase in intracellular cyclic guanosine 3', 5'-monophosphate. 6,7 PDNO release during platelet aggregation is now recognized as a negative-feedback mechanism to inhibit not only platelet aggregation 8 but also platelet recruitment. 9 Coronary risk factors are known to impair both EDNO [10] [11] [12] 7, 13, 14 however, there has not been a study measuring both EDNO and PDNO simultaneously in the same subjects, so it is still unknown whether impairment of these bioactivities coexist. Therefore, we investigated the relationship between EDNO and PDNO in patients with coronary risk factors.
signal. Drugs were then infused through the sheath. A femoral angiogram was performed to exclude obstructive disease in the femoral circulation. The average peak veloity during each intervention was recorded. Because diameter measurements were not made at the level of the Doppler wire with each intervention, we calculated the femoral vascular resistance index (FVRI, mmHg·cm -1 ·s -1 ) as the mean arterial pressure divided by femoral blood flow velocity. To exclude any significant changes in femoral artery diameter at the site of the flow wire during conditions of increased blood flow, we measured femoral artery diameter at the site of the flow wire during administration of acetylcholine (ACh; 400 g/min) and nitroglycerine (NTG; 200 g/min) in 10 patients. There was no significant change in femoral artery diameter at the site of the flow wire during these drug infusions: baseline, 4.8±0.7 mm, ACh, 4.8± 0.7 mm and NTG, 4.8±0.7 mm (all p = NS compared with baseline).
After the baseline measurements of flow velocity and mean arterial blood pressure, 2-min serial infusions of ACh at 50, 100, 200 and 400 g/min were performed. After recovery and return to baseline values, NTG was serially administered at 50, 100 and 200 g/min for 3 min. Peak flow velocity and arterial blood pressure were measured after each intervention.
Preparation of Gel-Filtered Platelets
Peripheral venous blood (20 ml) was drawn before examination of the FVRI, and gel-filtered platelets were prepared as described previously. 9 Briefly, the citrated blood was centrifuged (150 G, 15 min, 22°C) and the platelet-rich plasma was separated and passed over a Sepharose-2B column equilibrated with HEPES-Tyrode's buffer without Ca 2+ . The platelet counts were finally adjusted to 2×10 5 platelets/ L in Tyrode's solution.
Measurements of PDNO With an NO-Specific Electrode
We measured PDNO using an electronic NO meter (Model N0-501, Inter Medical Co) as described previously. 7, 13, 14 The NO meter and electrodes were placed in an electromagnetic shield box to avoid electrical perturbation. The electrodes were placed in the chamber containing the gel-filtered platelets and after the addition of Ca 2+ and fibrinogen, followed by ADP (5 mol/ml), the working electrode was supplied with +0.6 V for electrochemical oxidation of NO. The change in the peak electrical current was considered the index of NO release.
Statistical Analysis
Data are expressed as mean ± SD. The relationship between 2 parameters was analyzed by linear regression.
Statistical significance was considered at p<0.05.
Results
Clinical Characteristics (Table 1) The mean number of risk factors was 2.5±1.0, and the composite risk factor was 1 in 4 patients, 2 in 8, 3 in 8, and 4 in 4.
Vascular Responses and Coronary Risk Factors
ACh-mediated changes in the FVRI significantly correlated with the number of risk factors (r=-0.53, p<0.01; r= -0.54, p<0.01; r=-0.61, p<0.01; and r=-0.70, p<0.01 at 50, 100, 200, and 400 g/min of ACh, respectively (Fig 1A) , but the NTG-mediated changes did not (Fig 1B) .
PDNO Release and Coronary Risk Factors
Mean PDNO was 14.5±6.5 pA (range 6-27 pA), and PDNO release negatively correlated with the number of risk factors (r=-0.55, p<0.01; Fig 1C) .
Relationship Between Vascular Responses and PDNO Release
PDNO release significantly correlated with the AChmediated changes in FVRI at 50, 100, 200, and 400 g/min of ACh (Fig 2) . PDNO release did not correlate with the NTG-mediated changes (data not shown).
Discussion
ACh is commonly used as a probe for evaluating endothelial function, especially EDNO releasing capac- ity, 1,2 and NTG is used to test endothelium-independent vasodilator function in humans. In previous studies, the number of coronary risk factors has correlated with impaired ACh-mediated vasodilation in patients with coronary atherosclerosis and risk factors, 10-12 and we had a similar result in the human femoral circulation. This abnormality is usually attributed to decreased EDNO, which is synthesized from L-arginine via NOS in the endothelial cells. An NO-selective electrode is specifically capable of measuring real-time release of NO from aggregating platelets, 17 and we have previously confirmed that the change in the electrical current obtained by the NO-selective electrode reflects the amount of NO released through the L-arginine/NO pathway in aggregating human platelets. 7 Recently, we demonstrated that the number of coronary risk factors correlates with the degree of an impairment of PDNO release by human platelets, 13 and we had a similar finding in the present study. All these findings suggest that the L-arginine/NO pathway, which is a negative feedback mechanism that inhibits platelet aggregation, is indeed impaired in patients with coronary risk factors. Thus, both EDNO and PDNO bioactivities are more impaired when there are more risk factors. Importantly, ACh-mediated changes in the FVRI were significantly related to PDNO release and taken together, to the best of our knowledge, our data are the first demonstration that EDNO and PDNO are correlated in humans, and that the Larginine/NO pathway is impaired in both endothelial cells and platelets in patients with coronary risk factors. The underlying mechanisms are still unknown, but these impairments may be explained by increased oxidative stress as a common cascade, which impairs the release of NO or augments the inactivation of NO in patients with coronary risk factors. 3, 18 Indeed, we have previously shown that impaired PDNO bioactivity and augmented platelet aggregability in smokers may be caused by an imbalance of the intraplatelet redox state through increased oxidative stress. 14, 19 In general, EDNO and PDNO act in coordination as anti-atherothrombogenic molecules, 3, 4, 8, 9 and in the previous clinical studies, impaired EDNO or PDNO has been associated with an increase in cardiovascular events such as acute coronary syndromes. 20, 21 Accordingly, impaired EDNO and PDNO bioactivities may synergistically contribute to atherothrombogenesis in patients with coronary risk factors.
Study Limitations
First, the relatively small number of the subjects might have affected the results, but despite this, a significant correlation was found between EDNO and PDNO. Second, the contributions of endothelium-derived hyperpolarization factor and other vasodilating factors to ACh-induced vasodilation were not considered, but it has been demonstrated that the vasodilating effect of ACh is mainly caused by EDNO. 22 In conclusion, we have contributed to the understanding of the pathophysiology of atherothrombosis by demonstrating that both EDNO and PDNO bioactivities are impaired in patients with coronary risk factors, which suggests that both are involved in atherogenesis.
